Status:
COMPLETED
Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics
Lead Sponsor:
Sun Ying-Shi
Conditions:
Locally Advanced Rectal Cancer
Eligibility:
All Genders
Brief Summary
This study plans to construct a MR radiomics model for predicting pathological complete response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC) patients.
Detailed Description
We propose to develop and validate a radiomics model for individualized pCR evaluation after CRT in patients with LARC. We plan to use both pre- and post-CRT MRI data to construct the predictive radio...
Eligibility Criteria
Inclusion
- pathologically proved rectal cancer
- locally advanced rectal cancer (≥T3 or N+)
- a distance less than 12cm between the lower edge of tumor and the anal margin
- no evidence of distant metastases
- no prior anti-cancer therapy before treatment
- scheduled to receive preoperative CRT
Exclusion
- history or concurrent of other malignancy
- incomplete preoperative CRT
- failed to receive surgery or unavailable pCR assessment
- poor quality of MR images for measurement
- patient quit
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 21 2019
Estimated Enrollment :
538 Patients enrolled
Trial Details
Trial ID
NCT03238885
Start Date
March 1 2013
End Date
January 21 2019
Last Update
February 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142